159 related articles for article (PubMed ID: 31842658)
1. Long-term adherence to GnRH agonists in men with prostate cancer. A nation-wide population-based study in prostate cancer data base Sweden.
George G; Garmo H; Rudman S; Holmberg L; Robinson D; Stattin P; Adolfsson J; Van Hemelrijck M
Scand J Urol; 2020 Feb; 54(1):20-26. PubMed ID: 31842658
[No Abstract] [Full Text] [Related]
2. Androgen Deprivation Therapies and Changes in Comorbidity: A Comparison of Gonadotropin-releasing Hormone Agonists and Antiandrogen Monotherapy as Primary Therapy in Men with High-risk Prostate Cancer.
Beckmann K; Garmo H; Adolfsson J; Bosco C; Johansson E; Robinson D; Holmberg L; Stattin P; Van Hemelrijck M
Eur Urol; 2019 Apr; 75(4):676-683. PubMed ID: 30497883
[TBL] [Abstract][Full Text] [Related]
3. Anti-androgen monotherapy versus gonadotropin-releasing hormone agonists in men with advanced, non-metastatic prostate cancer: a register-based, observational study.
Thomsen FB; Bosco C; Garmo H; Adolfsson J; Hammar N; Stattin P; Van Hemelrijck M
Acta Oncol; 2019 Jan; 58(1):110-118. PubMed ID: 30375907
[TBL] [Abstract][Full Text] [Related]
4. Risk of cardiovascular events in men on abiraterone or enzalutamide combined with GnRH agonists: nation-wide, population-based cohort study in Sweden.
George G; Vikman H; Gedeborg R; Lissbrant IF; Garmo H; Styrke J; Van Hemelrijck M; Stattin P
Acta Oncol; 2021 Apr; 60(4):459-465. PubMed ID: 33606571
[TBL] [Abstract][Full Text] [Related]
5. Drugs for metabolic conditions and prostate cancer death in men on GnRH agonists.
Bosco C; Wong C; Garmo H; Crawley D; Holmberg L; Hammar N; Adolfsson J; Stattin P; Van Hemelrijck M
BJU Int; 2018 Feb; 121(2):260-267. PubMed ID: 28940667
[TBL] [Abstract][Full Text] [Related]
6. Gonadotropin-releasing Hormone Agonists, Orchiectomy, and Risk of Cardiovascular Disease: Semi-ecologic, Nationwide, Population-based Study.
Thomsen FB; Sandin F; Garmo H; Lissbrant IF; Ahlgren G; Van Hemelrijck M; Adolfsson J; Robinson D; Stattin P
Eur Urol; 2017 Dec; 72(6):920-928. PubMed ID: 28711383
[TBL] [Abstract][Full Text] [Related]
7. Association between duration and type of androgen deprivation therapy and risk of diabetes in men with prostate cancer.
Crawley D; Garmo H; Rudman S; Stattin P; Häggström C; Zethelius B; Holmberg L; Adolfsson J; Van Hemelrijck M
Int J Cancer; 2016 Dec; 139(12):2698-2704. PubMed ID: 27557616
[TBL] [Abstract][Full Text] [Related]
8. Incidence of fractures causing hospitalisation in prostate cancer patients: results from the population-based PCBaSe Sweden.
Thorstenson A; Bratt O; Akre O; Hellborg H; Holmberg L; Lambe M; Bill-Axelson A; Stattin P; Adolfsson J
Eur J Cancer; 2012 Jul; 48(11):1672-81. PubMed ID: 22386317
[TBL] [Abstract][Full Text] [Related]
9. Exploring the association between use of gonadotropin releasing hormones agonists and prostate cancer diagnosis per se and diabetes control in men with type 2 diabetes mellitus: a nationwide, population-based cohort study.
Lin E; Garmo H; Van Hemelrijck M; Adolfsson J; Stattin P; Zethelius B; Crawley D
BMC Cancer; 2021 Nov; 21(1):1259. PubMed ID: 34809595
[TBL] [Abstract][Full Text] [Related]
10. Does a prostate cancer diagnosis affect management of pre-existing diabetes? Results from PCBaSe Sweden: a nationwide cohort study.
Crawley D; Garmo H; Rudman S; Stattin P; Zethelius B; Armes J; Holmberg L; Adolfsson J; Van Hemelrijck M
BMJ Open; 2018 Mar; 8(3):e020787. PubMed ID: 29549214
[TBL] [Abstract][Full Text] [Related]
11. Gonadotropin-releasing hormone agonists and acute kidney injury in patients with prostate cancer.
Gandaglia G; Sun M; Hu JC; Novara G; Choueiri TK; Nguyen PL; Schiffmann J; Graefen M; Shariat SF; Abdollah F; Briganti A; Montorsi F; Trinh QD; Karakiewicz PI
Eur Urol; 2014 Dec; 66(6):1125-32. PubMed ID: 24495466
[TBL] [Abstract][Full Text] [Related]
12. Association of Gonadotropin-Releasing Hormone Agonists for Prostate Cancer With Cardiovascular Disease Risk and Hypertension in Men With Diabetes.
Lin E; Garmo H; Van Hemelrijck M; Zethelius B; Stattin P; Hagström E; Adolfsson J; Crawley D
JAMA Netw Open; 2022 Aug; 5(8):e2225600. PubMed ID: 35939302
[TBL] [Abstract][Full Text] [Related]
13. Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma.
Shahinian VB; Kuo YF; Freeman JL; Orihuela E; Goodwin JS
Cancer; 2005 Apr; 103(8):1615-24. PubMed ID: 15742331
[TBL] [Abstract][Full Text] [Related]
14. Risk of cardiovascular disease following gonadotropin-releasing hormone agonists vs antagonists in prostate cancer: Real-world evidence from five databases.
George G; Garmo H; Scailteux LM; Balusson F; De Coster G; De Schutter H; Kuiper JG; Oger E; Verbeeck J; Van Hemelrijck M
Int J Cancer; 2021 May; 148(9):2203-2211. PubMed ID: 33186481
[TBL] [Abstract][Full Text] [Related]
15. Work-up and treatment of prostate cancer before and after publication of the first national guidelines on prostate cancer care in Sweden.
Nugin H; Folkvaljon Y; Damber JE; Adolfsson J; Robinson D; Stattin P
Scand J Urol; 2018 Aug; 52(4):277-284. PubMed ID: 30362868
[TBL] [Abstract][Full Text] [Related]
16. Real-world insights into risk of developing cardiovascular disease following GnRH agonists versus antagonists for prostate cancer: a methodological protocol to a study using five European databases.
George G; Scailteux LM; Garmo H; Balusson F; Cardwell C; Coster G; Schutter H; Kuiper JG; McMenamin Ú; Verbeeck J; Van Hemelrijck M
Fundam Clin Pharmacol; 2019 Aug; 33(4):479-499. PubMed ID: 30776136
[TBL] [Abstract][Full Text] [Related]
17. Risk of prostate cancer death after radical radiotherapy with neoadjuvant and adjuvant therapy with bicalutamide or gonadotropin-releasing hormone agonists.
Bonde TM; Garmo H; Stattin P; Nilsson P; Gunnlaugsson A; Swanberg D; Robinson D
Acta Oncol; 2023 Dec; 62(12):1815-1821. PubMed ID: 37850633
[TBL] [Abstract][Full Text] [Related]
18. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer.
Smith MR; Lee WC; Brandman J; Wang Q; Botteman M; Pashos CL
J Clin Oncol; 2005 Nov; 23(31):7897-903. PubMed ID: 16258089
[TBL] [Abstract][Full Text] [Related]
19. Association of androgen deprivation therapy with thromboembolic events in patients with prostate cancer: a systematic review and meta-analysis.
Guo Z; Huang Y; Gong L; Gan S; Chan FL; Gu C; Xiang S; Wang S
Prostate Cancer Prostatic Dis; 2018 Nov; 21(4):451-460. PubMed ID: 29988099
[TBL] [Abstract][Full Text] [Related]
20. Time to castration-resistant prostate cancer and prostate cancer death according to PSA response in men with non-metastatic prostate cancer treated with gonadotropin releasing hormone agonists.
Bonde TM; Westerberg M; Aly M; Eklund M; Adolfsson J; Bill-Axelson A; Garmo H; Stattin P; Robinson D
Scand J Urol; 2022 Jun; 56(3):169-175. PubMed ID: 35548951
[No Abstract] [Full Text] [Related]
[Next] [New Search]